Real-World Patient Responsiveness and Safety of Long-Acting Beta Agonists in Asthma

The aims of this study are to: 1) Determine the effectiveness of Long-Acting Beta Agonists (LABA) controlling therapies in comparison with other available controller regimens in persistent asthma disease management. 2) Determine if LABA-containing therapies are associated with an increased risk of asthma-related severe adverse events (AEs). 3) Determine the characteristics of patients who clinically respond to, or have adverse events attributable to, LABA-containing therapies.

0